Related Experiment Video
Updated: Aug 5, 2026
Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
De-Escalation of Neoadjuvant Treatment for HER2-Positive Breast Cancer
Yiyin Ma1, Dedian Chen1, Sheng Huang1
1Yunnan Key Laboratory of Breast Cancer Precision Medicine, The Second Department of Breast Surgery, Breast Cancer Center of the Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Yunnan Cancer Center, Peking University Cancer Hospital Yunnan, Kunming, China.
None:
With improved prognosis in early HER2-positive breast cancer, safely de-escalating treatment is increasingly investigated to minimize overtreatment. This article focuses on neoadjuvant de-escalation strategies for HER2-positive breast cancer. There have been initiatives to shorten the duration of anti-HER2 therapy or to reduce the use of chemotherapy agents. Predictive or prognostic biomarkers and imaging techniques might help to identify subsets of patients within HER2-positive cancer with the best chance of responding to treatment and benefiting from de-escalated treatment.
